Business context and reporting period
The filing is MEDNAX, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2015. MEDNAX provides physician services—including neonatal, anesthesia, maternal-fetal, pediatric and radiology services—and related revenue-cycle and consulting services. The request metadata names Pediatrix Medical Group; the registrant named in the filing is MEDNAX, Inc.
Unless otherwise noted, financial amounts below are in U.S. dollars and millions.
Financial results and key metrics
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Revenue | $676.6 | $595.5 | $1,316.0 | $1,161.9 |
| Operating income | $141.0 | $129.7 | $255.8 | $233.8 |
| Operating margin | 20.8% | 21.8% | 19.4% | 20.1% |
| Net income attributable to MEDNAX | $84.1 | $79.0 | $152.8 | $142.7 |
| Diluted EPS | $0.90 | $0.79 | $1.62 | $1.42 |
| Adjusted EPS (non-GAAP) | $1.02 | $0.88 | $1.85 | $1.60 |
| EBITDA (non-GAAP) | $156.6 | $140.0 | $285.1 | $254.5 |
- Revenue increased 13.6% in Q2 and 13.3% in the first half. Acquisitions accounted for $79.0 million of Q2 revenue growth and $141.5 million of first-half growth. Same-unit revenue rose 0.4% and 1.1%, respectively.
- Operating income rose 8.7% in Q2 and 9.4% in the first half, but operating margins contracted by 94 and 68 basis points, respectively. Management attributed margin pressure primarily to the mix of acquired businesses.
- Interest expense was $5.1 million in Q2 and $8.4 million in the first half, up from $2.2 million and $3.6 million. Higher borrowing under the credit facility was the main reason.
- First-half operating cash flow was $92.4 million, versus $84.4 million in 2014. Investing cash outflow was $579.1 million, including $569.5 million for acquisitions and $12.7 million in capital expenditures. Financing cash inflow was $504.0 million.
- At June 30, cash and cash equivalents were $65.3 million; working capital was $213.7 million. The company reported $1.3 billion outstanding under its credit facility, comprising $1.1 billion on the revolver and a $195.0 million term loan; $602.8 million remained available.
- Accounts receivable were $380.5 million, and days sales outstanding increased to 51.2 from 49.8 at year-end, primarily reflecting recent acquisitions. Total professional-liability exposure was $209.8 million, including $25.9 million classified as current.
Material changes versus the prior comparable period
- Reported growth was primarily acquisition-driven. MEDNAX acquired seven physician practices and a radiology physician-services and telemedicine company; total consideration for the eight acquisitions was approximately $596.0 million, including cash acquired.
- Same-unit results were affected by lower Medicaid parity revenue: $3.0 million in Q2 2015 versus $16.0 million in Q2 2014, and $9.0 million in the first half versus $31.0 million. Excluding that decline, same-unit revenue growth was 2.6% in Q2 and 3.0% in the first half, as reported by management.
- Patient-service volume growth was partly offset by reimbursement pressure, including a greater share of patients covered by government healthcare programs. Management noted that these programs generally reimburse less than commercial payors.
- Weighted-average diluted shares fell to 93.5 million in Q2 and 94.4 million in the first half, from 99.9 million and 100.2 million. Repurchases contributed to the reduction and supported EPS growth. The company repurchased approximately 2.7 million shares for $233.6 million during the first half.
- Goodwill increased to $3,163.9 million from $2,776.2 million at December 31, 2014, largely reflecting acquisitions. The acquisition purchase-price allocations were preliminary.
Outlook, risks, contingencies and unusual items
- No numerical earnings or revenue guidance is provided. Management said operating cash generation, cash on hand and credit availability were expected to be sufficient for working capital, anticipated acquisitions, capital spending, share repurchases and contractual obligations for at least the next 12 months.
- Management expected to improve acquired practices through contracting, collections, growth initiatives and cost savings, and described the radiology and telemedicine acquisition as a platform for growth. These are expectations, not guarantees.
- Interest-rate exposure is material: a 1 percentage-point change in rates on the $1.3 billion credit-facility balance would affect annual pretax income by approximately $13.0 million. The company reported covenant compliance at June 30 and expected to remain compliant through 2015.
- Risks include reimbursement and payer-mix changes, patient bad debt, healthcare-law and Medicare payment changes, and the integration and margins of acquisitions. MEDNAX self-insures a portion of professional-liability risk; insurance may not cover all claims. Government audits, inquiries and investigations may have material effects, and no accrual was recorded for such matters because potential losses could not be reasonably estimated.
- Management believed pending legal proceedings would not materially affect results, while noting outcomes are uncertain. The filing reported no material changes to risk factors from the latest Form 10-K.
- Q2 included a $0.8 million reduction in contingent consideration liability recorded in operating income. First-half 2014 non-operating results included income from a favorable litigation settlement. The first-half 2015 cash-flow comparison was also affected by incentive-compensation payments.
Important facts for investors to verify
- Confirm the entity and ticker of interest: the filing identifies the registrant as MEDNAX, Inc., while the request metadata says Pediatrix Medical Group.
- Assess how much future growth depends on acquisitions versus same-unit volume and reimbursement; reported first-half growth was predominantly acquisition-related.
- Review acquisition integration, preliminary purchase-price allocations, goodwill and intangible-asset amortization, and whether acquired businesses achieve expected returns.
- Monitor debt, available revolver capacity, interest-rate sensitivity and compliance with credit-facility covenants.
- Track payer mix, Medicaid parity revenue, collections and DSO, along with professional-liability reserves and the outcome of government inquiries or legal claims.
- Interpret EBITDA and Adjusted EPS as company-defined non-GAAP measures alongside GAAP earnings and cash flow.